Dual Allosteric Effect in Glycine/NMDA Receptor Antagonism: A Comparative QSAR Approach

Manish Sharma¹,²* and Vipin B. Gupta¹

¹ Centre for QSAR and Molecular Modeling, Department of Medicinal and Pharmaceutical Chemistry, TIFAC-CORE, Innovation Square, B. R. Nahata College of Pharmacy (Scientific and Industrial Research Organization), Mandsaur, 458001, MP, India; E-Mail: vbgupta@hotmail.com (V.B.G.)
² Research Scholar at Jodhpur National University, Jodhpur (Raj), India

* Author to whom correspondence should be addressed; E-Mail: manish_bits@rediffmail.com; Tel.: +91-7422-255734; Fax: +91-7422-255506.

Received: 13 August 2010 / Accepted: 25 September 2010 / Published: 11 October 2010

Abstract: A comparative Hansch type QSAR study was conducted using multiple regression analysis on various sets of quinoxalines, quinoxalin-4-ones, quinazoline-2-carboxylates, 4-hydroxyquinolin-2(1H)-ones, 2-carboxytetrahydroquinolines, phenyl-hydroxy-quinolones, nitroquinolones and 4-substituted-3-phenylquinolin-2(1H)-ones as selective glycine/NMDA site antagonists. Ten statistically validated equations were developed, which indicated the importance of CMR, Verloop’s sterimol L1 and ClogP parameters in contributing towards biological activity. Interestingly, normal and inverse parabolic relationships were found with CMR in different series, indicating a dual allosteric binding mode in glycine/NMDA antagonism. Equations reveal an optimum CMR of 10 ± 10% is required for good potency of antagonists. Other equations indicate the presence of anionic functionality at 4-position of quinoline/quinolone ring system is not absolutely required for effective binding. The observations are laterally validated and in accordance with previous studies.

Keywords: allosterism; comparative QSAR; glycine/NMDA; CMR; quinoxalines

1. Introduction

The Central Nervous System (CNS) is regulated by excitatory and inhibitory amino acids known as neurotransmitters. A striking balance between the two maintains normal harmony of CNS physiology and overall well-being of an individual. A slight unbalance precipitates typical CNS disorders [1-6].
Receptors for excitatory neurotransmitters are classified into metabotropic (G-protein coupled receptors) and ionotropic (ligand gated ion channels) types [7]. Ionotropic receptors comprises of kainate, (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propionic acid (AMPA), and N-methyl-D-aspartic acid (NMDA) receptors. NMDA receptors are permeable to sodium, calcium, and potassium ions. Of paramount importance is permeability to Ca\(^{2+}\) ions, which confers on them an important role in synaptic plasticity under physiological condition and neuronal death under pathological conditions. Different binding sites on NMDA receptors allows a vast number of allosteric (allostery, a word of Greek origin meaning “another shape”) interactions, namely: glycine, polyamine, phencyclidine, zinc, magnesium, phosphorylation, as well as sites, which are prone to modulation by different pH or redox states [8-13]. Therapeutic benefit of strychnine insensitive glycine site is currently under investigation for different acute and chronic disorders, e.g. Alzheimer’s disease, Amyotrophic Lateral Sclerosis, Parkinson’s disease, Huntington’s Chorea, anxiety disorders, depressions, epilepsy, stroke, trauma and chronic pain [14]. The positive aspects of choosing glycine/NMDA receptor site as drug target are lack of vacuolization, learning impairment, or psychotomimetic effects, for glycine antagonists compared to competitive antagonists at the NMDA receptor or channel blockers.

Crum-Brown and Fraser [15] first laid the foundation of QSAR by proposing the idea that biological response is a function of chemical structure. A set of extra-thermodynamically derived and computationally based descriptors is employed to correlate in vitro or in vivo biological activity of a set of molecules. Generally such descriptors are lipophilic, electronic, steric or topologic in nature. Correlating these parameters with biological activity of a set of molecules provides valuable insight into molecular mechanism of binding interaction. However, choice of parameters is very important, as their availability has become quite handy. Numerous irrelevant parameters and their values are made available at the press of a key, which could not provide any information as to how a molecule is interacting with receptor. A stroke of chance could result in a statistically significant equation with one or other parameter. Although quite important, statistics alone could not discount the doubt and risk involved in a standalone QSAR equation. In the words of Ernest Rutherford, “If your experiment needs statistics, you ought to have done a better experiment.”

Comparative QSAR is the only methodology, which is ideally suitable to validate any given equation. It focuses upon the idea that same biological system (target receptor or enzyme) when interacts with different sets of series, the physicochemical properties involved in drug-receptor interaction generally remain similar [16]. Such equations laterally validate the observation obtained and attract authenticity. Comparison of such QSAR equations assists in understanding the mechanistic interpretation of drug-receptor binding and nature of subsite. Newer series could thus be proposed for further synthesis keeping the observations recorded from the equations and screening molecules through Lipinski’s “rule of five” for bioavailability check. Potential analogs from the proposed series could be further tested in tandem with molecular docking simulations to inspect whether they could potentially inhibit or stimulate the corresponding receptor subsite.

In present study, we have developed ten QSAR equations for various sets of selective glycine/NMDA antagonists to understand the ligand-receptor interaction and laterally validate the observations.
2. Experimental Section

2.1. The Data Set

Multiple regression analysis was performed to carry out QSAR study with Hansch approach on glycine site inhibiting activity of NMDA receptor of ten different series of quinoxalines, quinoxalin-4-ones, quinazoline-2-carboxylates, 4-hydroxyquinolin-2(1H)-ones, 2-carboxytetrahydroquinolines, phenylhydroxyquinolones, nitroquinolones and 4-substituted-3-phenylquinolin-2(1H)-ones to produce 50% inhibition of \([^3H]\) glycine or \([^3H]\)-L-689,560 binding to rat brain cortical membranes. The biological activity IC$_{50}$ of the compounds was collected from the literature and converted into molar concentrations. A negative logarithm of biological activity was used to provide better correlation with parameters and avoid clustering of data points; $-\log$IC$_{50}$ therefore becomes dependent variable in subsequent equations. The data table depicts various biological activities viz. observed by experimentation (Obs.), calculated by equation (Cal.), and externally predicted (Ext. Pred.). $\Delta$ indicates difference between Obs. and Cal. or Ext. Pred. activities.

2.2. Parameter Calculation

Physicochemical parameters for substituents of unionized molecules like ClogP, CMR and Verloop’s sterimol [17] L1 was obtained from MMP plus™ (www.norgwyn.com). Molar refractivity is based on Lorentz-Lorenz equation: $\text{MR} = (n^2 - 1)/(n^2 + 2)(\text{MW}/d)$ where $n$ is the index of refraction, $\text{MW}$ is molecular weight of the compound and $d$ is density. An interesting facet of MR is its dependency on combined effect of molecular volume and polarizability represented by $\text{MW}$ and $n$, respectively. However, the effect of polarizability is less as for most compounds the $n$ is in the range of 1.35–1.60 [18]. It is assumed that MR is a much better parameter than molecular volume [19]. A strong correlation indicates absence of polarizability effects and thus only bulkiness of the drug might be important in interacting with the receptor. To bring MR with the level of $\pi$ it was scaled down by 0.1. MR with a positive coefficient indicates involvement of dispersive forces in drug receptor interaction [20].

2.3. Chemometric Tools and Technique

A multiple linear regression based software QSAR (received from BITS-Pilani, India) generates QSAR equations and provides correlation coefficient ($r$), standard deviation ($s$), and ratio between variance of calculated and observed activities ($F$); $F = fr^2/(1 - r^2)m$, where $f$ is degree of freedom, $m$ is number of variables, $f = n - (m + 1)$, where $n$ is number of data points. $F$ value indicates true relationship or level of significance of QSAR equation.

In equations, the figure in parentheses is 95% confidence intervals and $F$ value in parenthesis is critical 99% confidence intervals. The software also provides intercorrelation matrix between descriptors. For internal validation, $r^2$ and $r^2_A$ were calculated to assess “goodness of fit” of the equation. $r^2$ value is variance between observed and calculated biological activity. An adjusted $r^2$ is $r^2_A$ and calculated by the formula, $r^2_A = r^2(1 - 1/F)$. $Q^2$ is cross-validated leave-one-out (L-O-O) $r^2$ between observed and predicted activity [21]. It measures quality of QSAR equation. Another statistical index to estimate the quality is $Q_y$, which is calculated by the ratio $r/s$. A high $Q_y$ (high $r$ and low $s$) indicates less probability...
of chance correlation between biological activity and parameters [22]. A squared correlation was also calculated between CMR and ClogP in each equation to ascertain the true role of each parameter.

For testing the validity of a model, 25% compounds of the training set were removed randomly to constitute a test set. A QSAR equation was generated on remaining compounds to predict activity of test set molecules. The activity in all series save carboxytetrahydroquinolines refers to molar concentration of the compound required to displace [3H]-L-689,560 binding to glycine site of NMDA receptor in rat brain membranes. In carboxytetrahydroquinolines, the displaced compound is [3H]Gly. Compounds were deemed to be outliers on the basis of their difference between observed and calculated activities, which should be greater than 2s. Biological activity of outliers was calculated from the final equation. Applicability domains of QSAR models were estimated wherever necessary by software AMBIT [23].

3. Results and Discussion

For all ten series of glycine site antagonists of NMDA receptors (I–VIII), as listed in Tables 1-8, the best correlations (Equations 1–10) obtained are summarized below along with externally validated Equations (1a–10a):

i. Inhibition of glycine/NMDA site by I (Table 1) [24].

\[-\log\text{IC}_{50} = 0.157(0.100)\text{CMR} + 1.139 (0.363)I_1 + 4.000(0.852)\]
\[n = 13, r=0.950, s=0.18, F_{2,10} = 45.93(7.56)\]
\[r^2 = 0.90, r^2_A = 0.88, Q^2 = 0.83, Q_3 = 5.28\]
CMR range = 6.21-10.16, outliers = 20, 22
\[r^2(\text{CMR vs. ClogP}) = 0.63\] (1)

\[-\log\text{IC}_{50} = 0.131(0.124)\text{CMR} + 1.119(0.394)I_1 + 4.277(1.049)\]
\[n = 10, r = 0.960, s = 0.17, F_{2,7} = 41.07(9.55)\]
\[r^2 = 0.92, r^2_A = 0.90, Q^2 = 0.84, Q_3 = 5.75\]
Excluded compounds = 8,14,17 (1a)

The activity in Equation (1) is largely governed by CMR, which reveals that there is an overall dispersion interaction of the molecule with the target receptor. Indicator variable \(I_1\) takes a value of 1 for compounds with conformational constraints in the form of triple bond and zero, if otherwise. A positive \(I_1\) coefficient indicates high electronic density moieties in the form of triple bond add to the potency of the molecule by strengthening dispersive forces involved in ligand-receptor interaction. Interestingly, CMR is a very good measure of dispersive force. A small correlation between CMR and ClogP presumably indicates that lipophilicity of molecules is also important but we could not obtain a good correlation with ClogP. Compounds 20 and 22 were not included in the equation as they exhibited inconsistent activities.
Table 1. A series of 4-hydroxyquinolin-2(1H)-ones, 3-esters I, with their structural parameters and binding affinities.

| C.N. | R                | I₁ | CMR | -logIC₅₀ | Obs. | Cal. | Δ     | Ext. Pred. | Δ     |
|------|------------------|----|-----|----------|------|------|-------|------------|-------|
| 8    | Et               | 0.00| 6.68| 4.78    | 5.05 | -0.27| 5.15  | -0.37      |
| 10   | Me               | 0.00| 6.21| 5.19    | 4.98 | 0.21 |
| 12   | Allyl            | 0.00| 7.09| 5.19    | 5.12 | 0.07 |
| 13   | Propargyl        | 0.00| 6.94| 5.04    | 5.09 | -0.05|
| 14   | CH₂-3-(phenol)   | 0.00| 8.78| 5.21    | 5.38 | -0.17| 5.43  | -0.22      |
| 15   | (CH₂)₂-3-(phenol)| 0.00| 9.24| 5.74    | 5.45 | 0.29 |
| 16   | (CH₂)₃-3-(phenol)| 0.00| 9.70| 5.58    | 5.52 | 0.06 |
| 17   | (CH₂)₄-3-(phenol)| 0.00| 10.16| 5.58   | 5.60 | -0.02| 5.43  | -0.03      |
| 18   | (CH₂)₂-2-(phenol)| 0.00| 9.24| 5.15    | 5.45 | -0.15|
| 19   | (CH₂)₂-4-(phenol)| 0.00| 9.24| 5.53    | 5.45 | 0.08 |
| 20   | (CH₂)₂-2-(pyridine)| 0.00| 9.02| 4.56⁺  | 5.42 | -0.86|
| 21   | (CH₂)₂-2-(thiophene)| 0.00| 9.01| 5.52    | 5.42 | 0.10 |
| 22   | (CH₂)₂-3-(indole)| 0.00| 10.14| 6.37⁺  | 5.59 | 0.78 |
| 23   | CH₂C≡C-4-(anisole)| 1.00| 9.97| 6.57    | 6.71 | -0.14|
| 24   | CH₂C≡C-4-(phenol)| 1.00| 9.50| 6.77    | 6.63 | 0.14 |

⁺ outlier

ii. Inhibition of glycine/NMDA site by II (Table 2) [24].

\[-\log IC_{50} = -0.440(0.219)\text{Clog}P + 0.230(0.070)\text{Clog}P^2 + 4.771(0.161)\]

\[n = 5, \ r = 0.997, \ s = 0.04, \ F_{1,3} = 165.81(34.12)\]

\[r^2 = 0.99, \ r^2_A = 0.99, \ Q^2 = 0.83, \ Q_y = 26.24\]

Inversion point = 0.96(0.65 – 1.16)

\[r^2(\text{CMR vs. Clog}P) = 0.032\] (2)

In the generation of Equation (2), activity seems to be dependent upon ClogP in an allosteric way. Activity decreases with ClogP upto inversion point and then increases. For good activity, ClogP of molecules atleast should be above inversion point (0.96). The observation gets support from the derivation of Equation (3), which indicates a positive linear relationship of biological activity with ClogP in a range above inversion point (1.22–2.70).
Table 2. A series of 3-(ethoxycarbonyl)-4-hydroxyquinolin-2(1H)-ones II, aromatic substitutions with their structural parameters and binding affinities.

iii. Inhibition of glycine/NMDA site by III (Table 3) [24].

\[-\log IC_{50} = 0.601(0.369)ClogP + 4.448(0.788)\]
\(n = 5, r = 0.948, s = 0.11, F_{1,3} = 26.85(34.12)\)
\(r^2 = 0.99, r^2_A = 0.99, Q^2 = 0.80, Q_y = 8.62\)
outliers: 9, 42 \(r^2(CMR\ vs.\ ClogP) = 0.352\) (3)

Table 3. A series of 4-hydroxyquinolin-2(1H)-ones, 3-ketones III, with their structural parameters and binding affinities.

iv. Inhibition of glycine/NMDA site by IV (Table 4)[25].

\[-\log IC_{50} = -0.235(0.076)L1 + 3.853(0.909)CMR\]
\(-0.176(0.045)CMR^2 - 0.549(0.260)I_2 - 12.124(4.378)\)
\( n = 18, r = 0.960, s = 0.14, F_{3,14} = 38.44(5.56) \)
\( r^2 = 0.92, r_A^2 = 0.90, Q^2 = 0.85, Q_y = 7.06 \)
CMR_o = 10.9 (10.7-11.3), outlier = 22
\( r^2 (\text{CMR vs. Clog}P) = 0.37 \)

\[-\log IC_{50} = -0.239(0.121)L1 + 3.895(0.719)\text{CMR} - 0.179(0.035)\text{CMR}^2 - 0.524(0.175)I_2 - 12.311(3.306) \]
\( n = 12, r = 0.98, s = 0.07, F_{3,8} = 81.95(7.59) \)
\( r^2 = 0.98, r_A^2 = 0.97, Q^2 = 0.94, Q_y = 13.36 \)
CMR_o = 11.00 (10.80-11.30)

Excluded compounds = 21, 14, 29, 30, 31

In Equation (4), again CMR emerges as an important parameter with normal allosteric effect. The CMR_o obtained is 10.9 (10.7-11.3). This equation is particularly interesting as it provides clues for further synthesis of promising molecules with an optimum CMR range. The negative coefficient of L1 indicates that probably a size limited lipophilic pocket is present near to substituent R in receptor, which does not allow lengthy substituents for efficient binding. Indicator variable \( I_2 \) stands with a value of unity for compounds with saturated ring as substituent at R and zero, if otherwise. A negative \( I_2 \) in equation reveals that saturated rings are not preferred probably because of their thin delocalized electron cloud, which renders them weak to participate in dispersive force interaction between molecule and receptor for binding.

**Table 4.** A series of trans-4-amido-2-carboxytetrahydroquinolines IV, with their structural parameters and binding affinities.

| C.N. | R          | CMR | L1   | I2   | \(-\log IC_{50}\) |
|------|------------|-----|------|------|---------------------|
|      |            |     |      |      | Obs. | Cal. | \(\Delta\) | Ext. Pred. | \(\Delta\) |
| 17   | CH\(_3\)   | 7.41 | 3.08 | 0.00 | 6.04 | 6.03 | 0.01      |            |           |
| 18   | \(n\)-Pr   | 8.33 | 5.28 | 0.00 | 6.43 | 6.50 | -0.07     |            |           |
| 19   | c-hexyl    | 9.50 | 5.23 | 1.00 | 6.77 | 6.80 | -0.03     |            |           |
| 20   | CH\(_2\)c-hexyl | 9.96 | 5.50 | 1.00 | 6.96 | 6.93 | 0.03      |            |           |
| 9    | Ph         | 9.36 | 6.27 | 0.00 | 7.00 | 7.03 | -0.03     |            |           |
| 21   | 2-furyl    | 8.65 | 5.26 | 0.00 | 6.82 | 6.79 | 0.03      | 6.74       | 0.08      |
| 22   | 4-pyridyl  | 9.29 | 5.19 | 0.00 | 6.20 | 7.26 | -1.06     |            |           |
| 14   | CH\(_2\)Ph | 9.82 | 4.59 | 0.00 | 7.92 | 7.64 | 0.28      | 7.58       | 0.34      |
| 23   | CH\(_2\)(3-thienyl) | 9.74 | 4.95 | 0.00 | 7.52 | 7.53 | -0.01     |            |           |
| 24   | CH\(_2\)(2-thienyl) | 9.74 | 4.56 | 0.00 | 7.52 | 7.62 | -0.10     |            |           |
| 25   | CH\(_2\)C\(_6\)H\(_4\)NH\(_2\)-4 | 10.16 | 5.28 | 0.00 | 7.70 | 7.60 | 0.10      |            |           |
| 26   | CH\(_2\)C\(_6\)H\(_4\)OH-4 | 9.97 | 5.22 | 0.00 | 7.52 | 7.55 | -0.03     |            |           |
Table 4. Cont.

|   |     |    |    |    |    |    |    |
|---|-----|----|----|----|----|----|----|
|27 | CH₂C₆H₄CH₃-4 | 10.28 | 6.00 | 0.00 | 7.52 | 7.46 | 0.06 |
|28 | CH₂C₆H₄OCH₃-4 | 10.45 | 5.63 | 0.00 | 7.40 | 7.58 | −0.18 |
|29 | CH₂C₆H₄Cl-4 | 10.31 | 5.62 | 0.00 | 7.30 | 7.55 | −0.25 | 7.48 | −0.18 |
|30 | (CH₂)₃Ph | 10.28 | 8.59 | 0.00 | 7.10 | 6.85 | 0.25 | 6.76 | 0.34 |
|31 | (CH₂)₃OCH₃-4 | 10.74 | 8.54 | 0.00 | 6.77 | 6.93 | −0.16 | 6.83 | −0.06 |
|32 | C₆H₄Cl | 12.23 | 5.80 | 0.00 | 7.22 | 7.28 | −0.06 | 6.83 | −0.18 |
|33 | 9-fluorenyl | 12.01 | 4.94 | 0.00 | 7.70 | 7.58 | 0.12 |

* Outlier

v. Inhibition of glycine/NMDA site by V (Table 5)[25].

\[ - \log IC_{50} = 0.430(0.193)CMR + 2.499(1.874) \]
\[ n = 6, r = 0.952, s = 0.11, F_{1,4} = 38.40(21.20) \]
\[ r^2 = 0.90, r^2_A = 0.88, Q^2 = 0.67, Q_y = 8.42 \]

CMR range = 8.14-10.49, outlier = 57
\[ r^2(CMR \text{ vs. } \text{Clog}P) = 0.31 \]  \hspace{1cm} (5)

\[ - \log IC_{50} = 0.412(0.222)CMR + 2.649(2.142) \]
\[ n = 5, r = 0.960, s = 0.11, F_{1,3} = 34.91(34.12) \]
\[ r^2 = 0.92, r^2_A = 0.89, Q^2 = 0.68, Q_y = 8.97 \]

Excluded compound = 54  \hspace{1cm} (5a)

Similarly CMR dominates Equation (5) with a positive regression coefficient in the range 8.14-10.49, which is a subset of CMR range witnessed in Equation (1), indicating both series I and V bind to the glycine site in a similar way.

Table 5. A series of conformationally restricted 4-substituents V, with their structural parameters and binding affinities.

| C.N. | R                        | CMR | \(-\log IC_{50}\) |
|------|--------------------------|-----|-------------------|
|      |                          | Obs | Cal.  | Δ       | Ext. Pred. | Δ     |
| 51   | 1-pyrrolidin-2-one       | 8.14| 6.04  | 6.00    | 0.04      |
| 52   | 1-isoindolin-1-one       | 9.63| 6.43  | 6.64    | −0.21     |
| 53   | 2-isoindoline-1,3-dione  | 9.80| 6.77  | 6.72    | 0.05      |
| 54   | 2-(1,2-dihydroiso-quinolin-3- (4H) one) | 10.09| 6.96  | 6.84    | 0.12      | 6.81  | 0.15 |
Table 5. Cont.

|   | C.N.                | R                      | CMR   | Obs.     | \(-\log{IC_{50}}\) | Cal. | Δ | Ext. Pred. | Δ |
|---|------------------|------------------------|-------|----------|---------------------|------|---|------------|---|
| 55| 1-(3-phenylimidazolidin-2-one) | 10.49                  | 7.00  | 7.01     | -0.01               |      |   |            |   |
| 56| 3-(3,4-dihydroquinazolin-2-(1H)-one) | 10.02                  | 6.82  | 6.81     | 0.01                |      |   |            |   |
| 57| -N-indoline-1-carboxamide       | 10.45                  | 6.20a | 6.99     | -0.79               |      |   |            |   |

\(^a\) Outlier

\(vi. Inhibition of glycine/NMDA site by VI (Table 6)[26].\)

\[- \log{IC_{50}} = -13.60 (9.66) \text{CMR} + 0.633 (0.45) \text{CMR}^2 + 81.45 (51.4)\]

\(n = 6, r = 0.940, s = 0.08, F_{1,4} = 11.42(21.20)\)

\(r^2 = 0.91, r^2_A = 0.89, Q^2 = 0.64, Q_y = 11.190\)

CMR range = 7.37–11.49, outlier = 6

Inversion point = 10.8(10.6–11.1), \(r^2(\text{CMR vs. ClogP}) = 0.61\) (6)

\[- \log{IC_{50}} = -14.61 (10.6) \text{CMR} + 0.681(0.50) \text{CMR}^2 + 86.71 (56.5)\]

\(n = 5, r = 0.975, s = 0.07, F_{1,3} = 19.49(34.12)\)

\(r^2 = 0.95, r^2_A = 0.93, Q^2 = 0.80, Q_y = 14.55\)

Excluded compound = 12

(6a)

In Equation (6), a negative allosteric effect with CMR is observed. Activity decreases with CMR upto inversion point (10.8) and then increases with further increase in CMR.

Table 6. A series of substituted 3-phenyl-4-hydroxy-2-quinolones VI, with their structural parameters and binding affinities.

\[\text{VI}\]

| C.N. | R                      | CMR   | Obs.     | \(-\log{IC_{50}}\) | Cal. | Δ | Ext. Pred. | Δ |
|---|------------------------|-------|----------|---------------------|------|---|------------|---|
| 6  | H                      | 7.37  | 6.77a    | 15.56               | -8.83 |   |            |   |
| 9  | CH\(_3\)Ph             | 10.24 | 8.39     | 8.49               | -0.10 |   |            |   |
| 10 | CH\(_3\)PhOMe-4        | 10.87 | 8.35     | 8.33               | 0.02  |   |            |   |
| 11 | CH\(_2\)PhOCH\(_2\)OMe-4 | 11.49 | 8.66     | 8.67               | -0.01 |   |            |   |
| 12 | CH\(_3\)(3-thienyl)    | 10.16 | 8.64     | 8.54               | 0.10  | 8.57 | 0.07       |   |
| 13 | OPh                    | 9.94  | 8.70     | 8.74               | -0.04 |   |            |   |
| 14 | O(3-thienyl)           | 9.86  | 8.85     | 8.83               | 0.02  |   |            |   |

\(^a\) Outlier
vii. Inhibition of glycine/NMDA site by VII (Table 7)[27].

$$-\log IC_{50} = -2.748(1.769)CMR + 0.140(0.093)CMR^2$$
$$+ 1.660(0.766)I_a + 16.958(7.869)$$

$$n = 10, r = 0.918, s = 0.21, F_{2,8} = 10.67(8.65)$$
$$r^2 = 0.87, r^2_A = 0.83, Q^2 = 0.42, Q_y = 4.41$$

Inversion point = 9.82(9.38-10.9), CMR range = 7.05-11.90

$$r^2(CMR \text{ vs. } ClogP) = 0.04 \quad (7)$$

$$-\log IC_{50} = -3.215(1.984)CMR + 0.162(0.105)CMR^2$$
$$+ 1.792(0.793)I_a + 19.166(8.815)$$

$$n = 7, r = 0.976, s = 0.14, F_{2,5} = 19.73(13.27)$$
$$r^2 = 0.95, r^2_A = 0.92, Q^2 = 0.77, Q_y = 7.18$$

Inversion point = 9.93(9.48-11.1)

Excluded compounds = 4, 16, 19

Equation (7) involves inverse allosteric effect with an inversion point of 9.82. Indicator variable $I_a = 1$ for compounds containing acidic moieties and zero for neutral and basic moieties. A positive $I_a$ indicates presence of acidic substituents is preferred which interacts with a proton acceptor site present in the glycine site close to R.

Table 7. A series of 3-nitro-3,4-dihydro-2(1H)-quinolones VII with their structural parameters and binding affinities.

| C.N. | R     | X   | $I_a$ | CMR | $-\log IC_{50}$ |
|------|-------|-----|------|-----|-----------------|
|      |       |     |      |     | Obs. | Cal. | Δ | Ext. Pred. | Δ |
| 4    | OH    | Cl  | 1.00 | 7.53| 5.88 | 5.86 | 0.02 | 5.85 | 0.03 |
| 13   | OCH$_2$COOMe | H   | 0.00 | 7.05| 4.54 | 4.54 | 0.00 |
| 14   | OCH$_2$COOH | Cl  | 1.00 | 7.51| 5.65 | 5.88 | -0.23 |
| 15   | OCH$_2$CONMe$_2$ | Cl  | 1.00 | 9.56| 5.25 | 5.14 | 0.11 |
| 16   | OCH$_2$CONH$_2$ | Cl  | 1.00 | 11.44| 5.74 | 5.50 | 0.24 | 5.39 | 0.35 |
| 17   | OCH$_2$CN | Cl  | 1.00 | 10.94| 5.12 | 5.30 | -0.18 |
| 18   | OCH$_2$-Pyr-2 | Cl  | 1.00 | 9.00| 4.91 | 5.22 | -0.31 |
| 19   | O(CH$_2$)$_2$NMMe$_2$ | Cl  | 1.00 | 9.49| 5.43 | 5.14 | 0.33 | 5.02 | 0.41 |
| 20   | OCH$_2$COMe | Cl  | 1.00 | 11.90| 5.60 | 5.74 | -0.14 |
| 21   | OCH$_2$(Me)=NOH | Cl  | 1.00 | 7.06| 6.38 | 6.19 | 0.19 |
viii. Inhibition of glycine/NMDA site by VIII (Table 8)[28].

\[ -\log IC_{50} = 7.965(3.677)CMR - 0.397(0.180)CMR^2 \]
+ 1.162(0.319)Ia − 34.426(18.651)
\[ n = 9, r = 0.977, s = 0.13, F_{2.6} = 34.32(10.92) \]
\[ r^2 = 0.95, r^2_A = 0.93, Q^2 = 0.84, Q_y = 7.29 \]
CMR_o = 10.0(9.76-10.20) CMR range = 7.56-11.56
Outliers = 3, 16, \( r^2(CMR \text{ vs. ClogP}) = 0.10 \) (8)

\[ -\log IC_{50} = 9.201(5.698)CMR - 0.457(0.280)CMR^2 \]
+ 1.217(0.517)Ia − 40.614(28.777)
\[ n = 7, r = 0.977, s = 0.12, F_{2.4} = 20.85(18.00) \]
\[ r^2 = 0.96, r^2_A = 0.94, Q^2 = 0.57, Q_y = 7.88 \]
CMR_o = 10.1(9.69-10.3), Excluded compounds = 6, 12 (8a)

In derivation of Equation (8), where heteroatom N of substituent R_1 is connected to 3-phenylquinolin-2(1H)-one nucleus, a positive allosteric effect is observed. Activity increases up to inversion point (CMR_o = 10) and then starts decreasing. Preference for acidic substituents is indicated by a positive coefficient of Ia. This equation could provide some clue in proposing molecules falling in optimum CMR range (9.76-10.20).

**Table 8.** A series of 4-substituted-3-phenylquinolin-2(1H)-ones VIII with their structural parameters and binding affinities.

| C.N. | X = R_1   | Ia   | CMR | –logIC50 |
|------|-----------|------|-----|----------|
|      |           |      |     | Obs.     | Cal. | Δ    | Ext. Pred. | Δ    |
| 3    | NH_2      | 0.00 | 7.56| 5.17^a  | 3.10 | 2.07 |
| 4    | NHCOMe    | 0.00 | 8.67| 4.83    | 4.81 | 0.02 |
| 6    | NHSO_2Me  | 1.00 | 9.62| 6.57    | 6.65 | −0.08 | 6.82 | −0.25 |
| 7    | NHSO_2Ph  | 1.00 | 11.57| 5.92    | 5.79 | 0.13 |
| 10   | NHCH_2Ph  | 0.00 | 10.45| 5.70    | 5.49 | 0.21 |
| 11   | NH(CH_2)_2NMMe_2 | 0.00 | 9.82 | 5.49 | 5.54 | −0.05 |
| 12   | NH(CH_2)_2NMMe_2 | 0.00 | 10.28| 5.38 | 5.53 | −0.15 | 5.68 | −0.30 |
| 13   | NHCOCOOH  | 1.00 | 9.00 | 6.24 | 6.29 | −0.05 |
| 14   | NHCOCOOMe | 0.00 | 9.47 | 5.57 | 5.43 | 0.14 |
| 15   | NHCOCONH(CH_2)_2NMMe_2 | 0.00 | 11.45| 4.60 | 4.77 | −0.17 |
| 16   | NHCOCH_2COOH | 1.00 | 9.46 | 5.96^a | 6.56 | −0.60 |

^a Outlier
ix. Inhibition of glycine/NMDA site by VIII (Table 9)[28].

\[-\log IC_{50} = 0.647(0.313)I_a - 1.289(0.325)\text{CMR} + 17.447(2.970)\]

\[n = 9, r = 0.974, s = 0.16, F_{2.6} = 56.05(10.92)\]

\[r^2 = 0.95, r^2_A = 0.932, Q^2 = 0.91, Q_y = 6.24\]

outlier = 1, CMR range = 4.94-6.96

\[r^2(\text{CMR vs. ClogP}):0.03\] (9)

\[-\log IC_{50} = 0.687(0.279)I_a - 1.237(0.285)\text{CMR} + 16.928(2.641)\]

\[n = 7, r = 0.990, s = 0.11, F_{2.4} = 99.79(18.00)\]

\[r^2 = 0.98, r^2_A = 0.97, Q^2 = 0.94, Q_y = 9.25\]

Excluded compounds = 22,27

In Equation (9), where heteroatom O of substituent R$_2$ is connected to 3-phenylquinolin-2(1H)-one nucleus, a negative linear relationship is observed with CMR. The equation also indicates a positive correlation with I$_a$.

Table 9. A series of 4-substituted-3-phenylquinolin-2(1H)-ones VIII with their structural parameters and binding affinities.

| C.N. | X = R$_2$ | I$_a$ | CMR | Obs. | Cal. | Ext. | Pred. | Δ |
|------|----------|------|-----|-----|-----|------|-------|---|
| 1    | OH       | 1.00 | 7.37| 6.77| 7.30| -0.53|       |   |
| 19   | OCH$_2$COOMe | 0.00 | 9.10| 5.49| 5.77| -0.28|       |   |
| 20   | OCH$_2$COOH | 1.00 | 8.63| 6.96| 6.17| 0.79 |       |   |
| 21   | OCH$_2$CONMe$_2$ | 0.00 | 9.80| 4.94| 5.18| -0.24|       |   |
| 22   | OCH$_2$CONH$_2$ | 0.00 | 8.82| 6.38| 6.03| 0.03 | 6.01 | 0.37|
| 23   | OCH$_2$CN  | 0.00 | 8.52| 6.49| 6.46| 0.03 |       |   |
| 25   | OCH$_2$-Pyr-2 | 1.00 | 9.77| 5.55| 5.60| -0.05|       |   |
| 26   | O(CH$_2$)$_2$NMe$_2$ | 0.00 | 9.62| 4.96| 5.00| -0.04|       |   |
| 27   | OCH$_2$COMe | 0.00 | 8.94| 5.77| 5.87| -0.10| 5.87 | -0.10|
| 28   | OCH$_2$C(Me)=NOH | 1.00 | 9.26| 6.11| 5.61| 0.50 |       |   |

*a Outlier

x. Inhibition of glycine/NMDA site by VIII (Table 10)[28].

\[-\log IC_{50} = 0.781(0.383)I_a + 12.130(7.142)\text{CMR} - 0.662(0.389)\text{CMR}^2 - 49.338(32.694)\]

\[n = 8, r = 0.959, s = 0.13, F_{2.5} = 15.37(13.27)\]

\[r^2 = 0.93, r^2_A = 0.90, Q^2 = 0.77, Q_y = 8.70\]

CMR$_0$ = 9.15(8.89-9.40), CMR range = 8.00-10.16, outlier = 39

\[r^2(\text{CMR vs. ClogP}) = 0.04\] (10)

\[-\log IC_{50} = 0.830(0.422)I_a + 11.264(7.739)\text{CMR} - 0.616(0.422)\text{CMR}^2 - 45.436(35.382)\]
A normal allosteric effect is again seen in Equation (10) with CMR, where carboxylic acid derivatives are substituted at 4-position in VIII. Activity increases up to inversion point (CMR_o=9.15) and then decreases with further increase in CMR. This equation again could provide clues in proposing newer molecules falling in the optimum CMR range. Acidic substituents are preferred as indicated by positive coefficient of \( I_a \).

Table 10. A series of 4-substituted-3-phenylquinolin-2(1H)-ones VIII with their structural parameters and binding affinities.

| C.N. | X=R          | \( I_a \) | CMR | \(-\log IC_{50}\)       |
|------|--------------|-----------|-----|--------------------------|
|      |              |           |     | Obs. | Cal. | \( \Delta \) | Ext. Pred. | \( \Delta \) |
| 31   | COOH         | 1.00      | 8.00| 6.04 | 6.06 | 0.02         |
| 33   | CH_2COOMe    | 0.00      | 8.94| 5.96 | 6.12 | 0.16         |
| 34   | CH_2COOH     | 1.00      | 8.46| 6.80 | 6.62 | 0.18         |
| 36   | CH_2CH_2COOCH_3 | 0.00     | 9.40| 6.30 | 6.10 | 0.20 | 6.02 | 0.28 |
| 37   | CH_2CH_2COOH | 1.00      | 8.93| 6.77 | 6.90 | 0.13         |
| 38   | (CH_2)_2-5-(3-methyl-1,2,4-oxadiazole) | 0.00 | 10.16| 5.46 | 5.47 | 0.01 |
| 39   | CH_2CH_2CONH_2 | 0.00     | 9.12| 6.72a| 6.23 | 0.49         |
| 40   | CH_2CH_2CN    | 0.00      | 8.82| 6.12 | 6.08 | 0.04         |
| 41   | (CH_2)_2-5-(1H-tetrazole) | 1.00  | 9.86| 6.62 | 6.59 | 0.03 |

\( a \) Outlier

A comparison of these ten equations elicits some very interesting points about the nature of the glycine site and the resulting mechanistic interpretation of its binding interactions. Out of ten equations CMR was found to be important in eight. All the equations satisfy statistical requirements. In data tables, \( \Delta \) values in two columns are in close proximity indicating strong correlation between internal and external predictivities.

Two different types of allosterism were observed in these equations: normal and inverse, especially with parameter CMR. To interpret contribution of CMR in equations is quite challenging. This parameter includes not only volume but also polarizability of molecule. Polarizability, in turn, is directional and attractive dispersive forces, arising out of the charge transfer reaction between molecule and receptor, cannot be established until both are of opposite nature.

In normal allosterism, activity increases in a linear fashion with CMR up to the inversion point where the quadratic term takes over and it decreases with further increase in CMR, resulting in a closed parabolic graph. Perhaps bulky molecules with some polarizability interact at an opportune position in receptor site and therefore activity increases. With further increase in bulkiness beyond the inversion point, steric hinderance of molecules affect binding and activity starts decreasing. Looking at Equations (4,8,10) with normal allosteric effects, the coefficient of linear portion of CMR in Equation (10) is thrice than in Equation (4) and twice than in Equation (8), indicating contribution of CMR in
activity variation is more in Equation (10). A similar CMR₀ of 10 (± 10%) and s (0.136, 0.134 and 0.130) in all three equations indicate similar binding mechanism. Lateral validation or comparison of QSARs thus establishes the authenticity of these three equations. In Equations (1,5), a positive linear relationship with CMR in the range 6.21-10.16 and 8.14-10.49, respectively, might show but not necessarily, normal allosterism. This could be revealed if further derivatives in higher CMR range are synthesized and tested. In Equations (2,3) although CMR is not present, still a weakly positive relationship similar to linear portion of Equation (4,8,10) is exhibit, suggestive of normal allosterism.

Interestingly, according to a belief, molecules with lower CMR than 10 (± 10%) not being active could be related to evolution in the receptor structure. Logistic modifications in structure and conformation of proteins made them insensitive towards unnecessary stimulation from various endogenous small ligands, which started appearing in cell cytoplasm and nucleoplasm with eons of time [18].

In inverse allosterism, activity decreases initially up to an inversion point and then increases with further increase in CMR resulting in an open parabolic graph. A negative allosteric effect is seen in Equations (6) and (7) with different coefficients of the linear portion of CMR. The CMR ranges where these equations hold applicable are similar [7.37–11.49 for Equation (6) and 7.05–11.90 for Equation (7)]. The point of inversion is 10.8 for Equation (6) and 9.82 for Equation (7). These two equations support each other’s observation; although, the variation in activity with CMR is different in each equation.

In Equation (9), a negative linear relationship with CMR in the range 4.94-6.96 could show inverse allosterism if some more derivatives are synthesized and tested in higher CMR range.

A bilinear relationship of Kubinyi type was also tested by the Bilin (www.kubinyi.de) software for equations where parabolic relationship was found, however the relationship was statistically insignificant.

Maximum effect of Iₐ is seen in Equations (7) and (8) with a large coefficient of 1.660 and 1.162 respectively. Since Iₐ is present in Equations (7,8,9 and 10), where both allosteric types are exhibited, it is tempting to speculate, that these binding mechanisms do not depend upon presence of anionic functionalities or acidic moieties or any other high electronic density fragments as substituents in a glycine site antagonist. This speculation is supported by a study of Carling et al. [28], who inferred that anionic functionality is not absolutely required for good activity and glycine site antagonists with neutral and basic moieties at 4-position of 3-phenylquinolin-2(1H)-ones performed equally well.

Our results of dual allosteric modes of binding for series VII and IV and V gets support from another observation of Carling et al. [27] who studied difference in structure activity relationships of these three series and indicated that they do not bind in an identical manner.

Certain QSAR studies although not conducted exhaustively are noteworthy. McQuaid et al. [29] conducted a QSAR analysis on a few 3-phenyl substituted-4-hydroxyquinolin-2(1H)-one compounds as glycine site antagonists (Equation 11) and observed a negative linear relationship of Hammett constant at para position σₚ with binding affinity. This indicates a positive effect of electron donating substituents at phenyl ring towards potency. A high electronic density in phenyl ring is therefore preferred.

$$-\log K_i = 0.95(0.18) - 1.26(0.41)\sigma_p$$

$$n = 6, r=0.84, F = 9.43, p = 0.04$$

(11)
Fabio et al. [30] synthesized some 3-substituted indole-2-carboxylates and conducted a QSAR study on them. The Equation (12) obtained reveals a negative linear relationship of summed MR and π values of substituents present at o,m and p positions of 3-phenyl ring. A negative linear correlation was also obtained with σ_p in the same equation which reveals presence of high electronic density phenyl ring is preferred.

\[ pK_i = -0.53MR_{omp} - 0.39\pi_{omp} - 0.82\sigma_p + 8.23 \]

\[ n = 25, r^2 = 0.84, s = 0.28, F = 37, p < 0.0001, r^2_{cv} = 0.76 \]  

(12)

The importance of MR and σ_p in Equations (11,12) indicates an electronic transfer reaction between the substituted 3-phenyl ring and some site on the receptor leading to involvement of dispersive forces. This study supports our results of CMR being an important parameter in most of our equations.

It is assumed that at the inversion point the structure of a receptor is forced to change into a new shape, which results in an altogether different type of interaction. A possibility could be that there is more than one binding site, but then it shouldn’t have been binding with the same parameters defined in the first half of the Equation [31]. The only way to confirm this allosteric interaction is by doing crystallographic studies of molecules present on both sides of inversion point.

Some outlier(s) were identified while generating equations, which were not considered in deriving the equation because of their arbitrary behaviour. In Equations (6 and 8), compounds 6 and 3 were treated as outliers, as their CMR values were too low than other derivatives in the series. The reason for anomalous behaviour of other outliers could not be attributed to a specific reason. Outlier identification in all equations was also judged by applicability domain estimation through William’s plot (HAT matrix leverage vs. L-O-O residuals).

A good range of data points was present on both sides of the parabola (positive and negative) and 95% confidence was present on the inversion point. These two checks confirm the quality of our conclusions.

We came across some studies involving 3D-CoMFA (Comparative Molecular Field analysis) methodology [32-36]. Although quite routinely reported; observations from such studies are difficult to compare with already established QSAR studies. CoMFA with its current status is semiquantitative in nature and does not qualify for quantitative SAR. Results generally are 3D pictures, which cannot be compared precisely. Moreover, the terms used to generate a regression-based model are based on principle components. These terms will have different composition from dataset to dataset so that comparison is impossible leaving pictures as the only tool to compare and conclude [15,18,22,31].

We have also considered some molecules, which have undergone clinical trials [14] (Figure 1). Interestingly, their CMR values are close to CMR_o (10 ± 10%). Such results indicate the quality of experimental work and validate the authenticity of equations. ClogP value was calculated for unionic ZD 9379 at pH = 7, which is in alignment with results from Equation (2) that lipophilicity of molecules should be above 0.96 for good activity. The rest have an ionizable carboxylic moiety in their structure and therefore would ionize at physiological pH = 7.4. ClogP values would therefore be different at two pH values. In such cases it is better to calculate logD values, if necessary.

Allosteric interaction has been inferred in previous studies by Bender et al. [37] and Hansch et al. [38]. Their results yield a normal and inverse parabolic relationship with molecular volume and CMR,
respectively. It is unknown where our results fit in the allosteric models first proposed by Monod, Wyman and Changeux [39] and later reviewed by Changeux and Edelstein [40]. Koshland et al. also proposed their pioneering work on protein allosterism [41]. These models depict changes in protein/receptor containing subunits. In drug discovery, allosteric interaction could be very advantageous in designing newer more efficacious molecules [42].

**Figure 1.** Some molecules having undergone clinical trials for treatment of stroke and/or neuropathic pain.

![Molecules](image)

**4. Conclusions**

The purpose of the study was to conduct comparative a QSAR study on various sets of selective glycine/NMDA antagonists to understand the ligand-receptor interaction mechanism and laterally validate the observations. A multiple linear regression of Hansch type analysis was employed. A test set of 25% molecules was excluded from the training set and their activities were predicted from the modified equations to assess the correlation between internal and external predictivities. CMR was found to be an important parameter in contributing to variation in biological activity. The presence of CMR in the equations reveals that dispersive forces are involved in drug-receptor interaction. Equations (4,8,10) and (6,7) indicated presence of normal and inverse allosterism at glycine site, respectively. Equations (2,3) indicated the importance of hydrophobic interactions. Verloop’s sterimol L1 was also found to be of use in Equation (4). Equations (4,8,10) revealed optimum CMR of 10 ± 10% is required for good activity. Through $I_a$, Equations (7,8,9,10) show the presence of anionic functionality at 4-position of quinoline/quinolone ring system is not absolutely required for effective binding. All the equations have been laterally validated and compared with previous observations in order to authenticate their results. We believe our equations could be helpful in designing more potent analogs.
Acknowledgements

One of the authors (MS) appreciates the contribution of Ruchi Malik in going through the manuscript and providing critical suggestions.

References

1. Choi, D.W. Calcium; still center-stage in hypoxic-ischemic neuronal death, *TINS* 1995, 18, 58-60.
2. Rothman, S.M.; Onley, J.W. Excitotoxicity and the NMDA receptor-still lethal after eight years. *TINS* 1995, 18, 57-58.
3. Bridges, R.J.; Stevens, D.R.; Kahle, J.S.; Nunn, P.B.; Kadri, M.; Cotman, C.W. Structure-function studies on N-oxalyl-diamino-dicarboxylic acids excitatory amino acids receptor; evidence that beta-L-ODAP is a selective non-NMDA agonist. *J. Neurosci.* 1989, 9, 2073-2079.
4. Meldrum, B.S. Excitotoxicity and selective neuronal loss in epilepsy. *Brain Pathol.* 1993, 3, 405-412.
5. Westerberg, E.; Monaghan, D.T.; Cotman, C.W.; Wieloch, T. Excitatory amino acids receptors and ischemic brain damage in the rat. *Neurosci. Lett.* 1987, 73, 119-124.
6. Wieloch, T. Hypoglycemia- induced neuronal damage prevented by an N-methyl-D-aspartate antagonists. *Science* 1985, 230, 681-683.
7. Leeson, P.D.; Iversen, L.L. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. *J. Med. Chem.* 1994, 37, 4053-4067.
8. McBain, C.J.; Mayer M.L. N-methyl-D-aspartic acid receptor structure and function. *Physiol. Rev.* 1994, 74, 723-760.
9. Moriyoshi, K.; Masu, M.; Ishii, T.; Shigemoto, R.; Mizuno, N.; Nakanishi, S. Molecular cloning and characterization of the rat NMDA receptor. *Nature* 1991, 354, 31-37.
10. Hollmann, M.; Heinemann, S. Cloned glutamate receptors. *Annu. Rev. Neurosci.* 1994, 17, 31-108.
11. Das, S.; Sasaki, Y.F.; Rothe, T.; Premkumar, L.S.; Takasu, M.; Crandall, J.E.; Dikkes, P.; Conner, D.A.; Rayudu, P.V.; Cheung, W.; Chen, H.S.V.; Lipton, S.A.; Nakanishi, N. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. *Nature* 1998, 393, 377-381.
12. Nishi, M.; Hinds, H.; Lu, H.P.; Kawata, M.; Hayashi, Y. Motoneuron-specific expression of nr3b, a novel nmda-type glutamate receptor subunit that works in a dominant-negative manner. *J. Neurosci.* 2001, 21, 1-6.
13. Chatterton, J.E.; Awobuluyi, M.; Premkumar, L.S.; Takahashi, H.; Talantova, M.; Shin, Y.; Cui, J.; Tu, S.; Sevarino, K.A.; Nakanishi, N.; Tong, G.; Lipton, S.A.; Zhang, D. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. *Nature* 2002, 415, 793-798.
14. Jansen, M.; Dannhardt, G. Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions. *Eur. J. Med. Chem.* 2003, 38, 661-670.
15. Hansch, C.; Hoekman, D.; Gao, H. Comparative QSAR: toward a deeper understanding of chemicobiological interactions. *Chem. Rev.* 1996, 96, 1045-1075.
16. Crum-Brown, A.; Fraser, T. On the connection between chemical constitution and physiological action. Part 1. On the physiological action of the ammonium bases, derived from Strychia, Brucia, Thebaia, Codeia, Morphia and Nicotia. *Trans. R. Soc. Edinburgh* 1868, 25, 151-203.
17. Verloop, A. QSAR and Strategies in the Design of Bioactive Compounds. In Proceedings of the 5th European Symposium on QSAR; Seydel, J.K., Ed.; VCH: Weinheim, Germany, 1985; pp. 98-104.
18. Hansch, C.; Garg, R.; Kurup A. Searching for allosteric via QSARs. Bioorg. Med. Chem. 2001, 9, 283-289.
19. Monod, J.; Changeux, J.P; Jacob, F. Allosteric proteins and cellular control systems. J. Mol. Biol. 1963, 6, 306-329.
20. Selassie, C.D.; Klein, T.E. In Comparative QSAR; Devillers, J., Ed.; Taylor and Francis: New York, 1998; pp. 235-284.
21. Cramer III, R.D.; Bunce, J.D.; Patterson, D. E.; Frank, I.E. Crossvalidation, bootstrapping, and partial least squares. compared with multiple regression in conventional. QSAR studies. Quant. Struct. Act. Relat. 1988, 7, 18-25.
22. Verma, R.P.; Hansch, C. Taxane analogues against breast cancer: a quantitative structure-activity relationship study. Chem. Med. Chem. 2008, 3, 642-652.
23. Jaworska, J.; Nikolova-Jeliazkova, N.; Aidenberg, T. QSAR applicability domain estimation by projection of the training set in descriptor space: a review. ATLA 2005, 33, 445-459.
24. Rowley, M.; Leeson, P.D.; Stevenson, G.I.; Mosley, A.M.; Stansfield, I.; Sanderson, I.; Robinson, L.; Baker, R.; Kemp, J.A.; Marshall, G.R.; Foster, A.C.; Grimwood, S.; Tricklebank, M.D.; Saywell, K.L. 3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically active anticonvulsants acting by antagonism at the glycine site of the N-Methyl-D-Aspartate receptor complex. J. Med. Chem. 1993, 36, 3386-3396.
25. Leeson, P.D.; Carling, R.W.; Moore, K.W.; Moseley, A.M.; Smith, J.D.; Stevenson, T.C.; Baker, R.; Foster, A.C.; Grimwood, S.; Kemp, J.A.; Marshall, G.R.; Hoogsteen, K. 4-Amido-2carboxytetrahydroquinolines. structure-activity relationships for antagonism at the glycine site of the NMDA receptor. J. Med. Chem. 1992, 35, 1954-1968.
26. Kulagowski, J.J.; Baker, R.; Curtis, N.R.; Leeson, P.D.; Mawer, I.M.; Moseley, A.M.; Ridgill, M.P.; Rowley, M.; Stansfield, I.; Foster, A.C.; Grimwood, S.; Hill, R.G.; Saywell, K.L.; Tricklebank, M.D. 3’-(aryl methyl)- and 3’-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor. J. Med. Chem. 1994, 37, 1402-1405.
27. Carling, R.W.; Leeson, P.D.; Moore, K.; Smith, J.D.; Moyes, C.R.; Mawer, I.M.; Thomas, S.; Chan, T.; Baker, R.; Foster, A.C.; Grimwood, S.; Kemp, J.A.; Marshall, G.R.; Tricklebank, M.D.; Saywell, K.L. 3-nitro-3,4-dihydro-2(1H)-quinolones. excitatory amino acid antagonists acting at glycine-site NMDA and (R)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J. Med. Chem. 1993, 36, 3397-3408.
28. Carling, R.W.; Leeson, P.D.; Moore, K.; Smith J.D.; Moyes, C.R.; Dunction, M.; Hudson, M.L.; Baker, R.; Foster, A.C.; Grimwood, S.; Kemp, J.A.; Marshall, G.R.; Tricklebank, M.D.; Saywell, K.L. 4-substituted-3-phenylquinolinol-2(1h)-ones: acidic and nonacidic glycine site n-methyl-d-aspartate antagonists with in vivo activity. J. Med. Chem. 1997, 40, 754-765.
29. McQuaid, L.A.; Smith, E.C.R.; Lodge, D.; Pralong, E.; Wikel, J.H.; Calligaro, D.O.; O’Malley, P.J. 3-phenyl-4-hydroxyquinoline-2(1h)-ones: potent and selective antagonists at the strychnine-insensitive glycine site on the n-methyl-d-aspartate receptor complex. J. Med. Chem. 1992, 35, 3423-3425.
30. Fabio, R.D.; Capelli, A.M.; Conti, N.; Cugola, A.; Donati, D.; Feriani, A.; Gastaldi, P.; Gaviraghi, G.; Hewkin, C.T.; Micheli, F.; Missio, A.; Mugnaini, M.; Pecunioso, A.; Quaglia, A.M.; Ratti, E.; Rossi, L.; Tedesco, G.; Trist, D.G. Reggiani, A. Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. J. Med. Chem. 1997, 40, 841-850.

31. Garg, R.; Kurup, A.; Mekapati, S.B.; Hansch, C. Searching for allosteric effects via QSAR. part ii. Bioorg. Med. Chem. 2003, 11, 621-628.

32. Baron, B.M.; Cregge, R.J.; Farr, R.A.; Friedrich, D.; Gross, R.S.; Harrison, B.L.; Janowick, D.A.; Matthews, D.; McCloskey, T.C.; Meikrantz, S.; Nyce, P.L.; Vaz, R.; Metz, W.A. CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylviny1)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2-carboxyvinyl]-4,6-dichloro-1H-indole-2-carboxylic acid, a potent selective glycine-site NMDA receptor antagonist. J. Med. Chem. 2005, 48, 995-1018.

33. Baskin, I.I.; Tikhonova, I.G.; Palyulin, V.A.; Zefirov, N.S. Selectivity fields: comparative molecular field analysis (CoMFA) of the Glycine/NMDA and AMPA receptors. J. Med. Chem. 2003, 46, 4063-4069.

34. Tikhonova, I.G.; Baskin, I. I.; Palyulin, V. A; Zefirov, N. S. CoMFA and homology-based models of the glycine binding site of N-methyl-D-aspartate receptor. J. Med. Chem. 2003, 46, 1609-1616.

35. Bacilieri M.; Varano F.; Deflorian F.; Marini M.; Catarzi D.; Colotta V.; Filacchioni G.; Galli A.; Costagli C.; Kaseda C.; Moro S. Tandem 3D-QSARs approach as a valuable tool to predict binding affinity data: design of new Gly/NMDA receptor antagonists as a key study. J. Chem. Inf. Model. 2007, 47, 1913-1922.

36. Patankar, S.J.; Jurs P.C. Prediction of glycine/NMDA receptor antagonist inhibition from molecular structure. J. Chem. Inf. Comput. Sci. 2002, 42, 1053-1068.

37. Bender, W.; Staudt, M.; Trankle, C.; Mohr, K. Probing the size of a hydrophobic binding pocket within the allosteric site of muscarinic acetylcholine M2-receptors. Life Sci. 2000, 66, 1675-1682.

38. Hansch, C.; Garg, R.; Kurup, A. Searching for allosteric effects via QSARS. Bioorg. Med. Chem. 2001, 9, 283-289.

39. Monod, J.; Wyman, J.; Changeux, J.-P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 1965, 12, 88-118.

40. Changeux, J.P.; Edelstein, S.J. Allosteric Receptors after 30 Years. Neuron, 1998, 21, 959-980.

41. Koshland, D.E., Jr. Application of a theory of enzyme specificity to protein synthesis. Proc. Natl. Acad. Sci. USA 1958, 44, 98-104.

42. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Rev. Drug Dis. 2002, 1, 198-210.